Akums Drugs and Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Akums Drugs and Pharmaceuticals has been growing earnings at an average annual rate of 47.1%, while the Life Sciences industry saw earnings growing at 18.1% annually. Revenues have been growing at an average rate of 6.2% per year. Akums Drugs and Pharmaceuticals's return on equity is 7.7%, and it has net margins of 5.9%.
Key information
47.12%
Earnings growth rate
46.20%
EPS growth rate
| Life Sciences Industry Growth | 11.24% |
| Revenue growth rate | 6.23% |
| Return on equity | 7.70% |
| Net Margin | 5.85% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
There May Be Reason For Hope In Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Disappointing Earnings
The market for Akums Drugs and Pharmaceuticals Limited's ( NSE:AKUMS ) shares didn't move much after it posted weak...Akums Drugs and Pharmaceuticals Limited Just Beat Revenue Estimates By 9.0%
Investors in Akums Drugs and Pharmaceuticals Limited ( NSE:AKUMS ) had a good week, as its shares rose 4.5% to close at...
AKUMS: Zambia Manufacturing Buildout Will Support Future Earnings Expansion
Analysts have kept their fair value estimate for Akums Drugs and Pharmaceuticals unchanged at ₹646.67, citing only modest tweaks to inputs such as a slightly lower discount rate and a marginally softer future P/E assumption, rather than any shift in the underlying company outlook. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).AKUMS: Zambia Expansion And Senior Leadership Moves Will Support Earnings
Analysts have kept their fair value estimate for Akums Drugs and Pharmaceuticals steady at ₹646.67, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. This reflects fine tuning of their models rather than a change in overall view.AKUMS: Zambia Manufacturing Buildout Will Support Future Margins And Earnings
Analysts have lifted their price target on Akums Drugs and Pharmaceuticals to ₹646.67 from ₹638.33, citing updated assumptions around revenue growth, profit margins, and a slightly different forward P/E framework. What's in the News The Board approved an investment of US$24 million (about ₹2,000 million) in Akums Healthcare (Zambia) Private Limited, a recently incorporated subsidiary in Zambia, to be infused through equity and or debt secured by MIGA insurance (Board meeting filing).AKUMS: Zambian Manufacturing Expansion Will Support Future Earnings And Margin Strength
Analysts have modestly revised their price target for Akums Drugs and Pharmaceuticals to ₹638.33 per share, reflecting slightly lower discount rate and future P/E assumptions while maintaining their outlook on revenue growth and profit margins. What's in the News The board has approved a USD 24 million (about INR 2,000 million) investment in subsidiary Akums Healthcare Zambia to establish a manufacturing facility and expand its presence in Zambia and neighboring African markets, with funding via equity and/or debt secured by MIGA insurance (Key Developments).AKUMS: Zambian Expansion Will Drive Earnings Momentum And Future Market Reach
Analysts have maintained their price target for Akums Drugs and Pharmaceuticals at ₹638.33, noting only minimal adjustments to underlying assumptions such as the discount rate and future earnings expectations. What's in the News The board of Akums Drugs and Pharmaceuticals approved an investment of USD 24 million (INR 2000 million approx.) in its Zambian subsidiary to establish a manufacturing facility and expand business in African markets (Board Meeting, Nov 13, 2025).AKUMS: Investment in Zambia Subsidiary Will Drive Stronger Earnings Momentum
Analysts have revised their price target for Akums Drugs and Pharmaceuticals downward from ₹691.67 to ₹638.33, citing updated assessments of growth prospects and market conditions. What's in the News A board meeting is scheduled for November 13, 2025, at 14:30 IST to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Major Pharma Contract And Global Expansion Will Forge Future Promise
Long-term export contract, product diversification, and international expansion are driving predictable revenue growth, profitability, and geographic risk mitigation.Concerns Surrounding Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Performance
Akums Drugs and Pharmaceuticals Limited ( NSE:AKUMS ) just released a solid earnings report, and the stock displayed...Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS) Not Flying Under The Radar
Akums Drugs and Pharmaceuticals Limited's ( NSE:AKUMS ) price-to-earnings (or "P/E") ratio of 57.6x might make it look...Revenue & Expenses Breakdown
How Akums Drugs and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 43,590 | 2,552 | 7,538 | 0 |
| 31 Dec 25 | 42,597 | 3,182 | 7,801 | 0 |
| 30 Sep 25 | 41,105 | 3,171 | 7,664 | 0 |
| 30 Jun 25 | 41,261 | 3,415 | 7,572 | 0 |
| 31 Mar 25 | 41,211 | 3,382 | 7,573 | 0 |
| 31 Dec 24 | 40,103 | 1,492 | 7,408 | 0 |
| 30 Sep 24 | 40,827 | 2,778 | 7,277 | 0 |
| 30 Jun 24 | 42,309 | 2,444 | 7,115 | 0 |
| 31 Mar 24 | 41,817 | -40 | 6,918 | 0 |
| 31 Dec 23 | 41,513 | 504 | 6,376 | 0 |
| 30 Sep 23 | 39,875 | -1,302 | 6,555 | 0 |
| 30 Jun 23 | 37,158 | -1,277 | 6,258 | 0 |
| 31 Mar 23 | 36,572 | 949 | 6,291 | 0 |
| 31 Mar 22 | 36,752 | -2,525 | 5,399 | 0 |
| 31 Mar 21 | 27,262 | 1,227 | 4,541 | 0 |
Quality Earnings: AKUMS has high quality earnings.
Growing Profit Margin: AKUMS's current net profit margins (5.9%) are lower than last year (8.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKUMS's earnings have grown significantly by 47.1% per year over the past 5 years.
Accelerating Growth: AKUMS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AKUMS had negative earnings growth (-24.5%) over the past year, making it difficult to compare to the Life Sciences industry average (16.1%).
Return on Equity
High ROE: AKUMS's Return on Equity (7.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 12:19 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akums Drugs and Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Pranav Chawla | Ambit Capital |
| Gaurav Tinani | Ambit Capital |